NIH Funding Opportunities (RSS Feed)

GenitoUrinary Development Molecular Anatomy Project (GUDMAP) - Atlas Projects (U01 Clinical Trial Not Allowed)

November 23, 2020

Funding Opportunity RFA-DK-20-013 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) requests applications for GUDMAP Atlas Projects to generate data for the GUDMAP database. The scope of Atlas Projects is limited to molecular and anatomical development of human and mouse (1) lower urinary tract, including ureters, bladder, urethra, prostate, and external male genitalia; and (2) kidney and lower urinary tract vasculature, nerves, and lymphatics. The GUDMAP Atlas Projects will be part of the GUDMAP consortium which was established to generate a molecular anatomy atlas of the developing mouse and human kidney and lower urinary tract. The GUDMAP consortium is expected to be a continuing resource for the research community and its long-term objective is to establish a comprehensive understanding of kidney and lower urinary tract development and maturation to inform the study of tissue maturation and aging, organ dysgenesis and disease, and ultimately organ repair and regeneration. A separate FOA seeks applications for the Data Hub (RFA-DK-20-014).

Notice of Change: Clarification of Page Limits for RFA-EY-20-001 "NEI Audacious Goals Initiative: Translation-Enabling Models to Evaluate Survival and Integration of Regenerated Neurons in the Visual System (U24 Clinical Trial Not Allowed)"

November 23, 2020

Notice NOT-EY-21-003 from the NIH Guide for Grants and Contracts

Notice of Clarification of SB1 Resubmission/Submission Policy

November 23, 2020

Notice NOT-OD-21-027 from the NIH Guide for Grants and Contracts

Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)

November 23, 2020

Funding Opportunity PAR-21-069 from the NIH Guide for Grants and Contracts. This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Studies that move the science of HIV and aging into new directions with little or no preliminary data are appropriate for this activity code.

Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)

November 23, 2020

Funding Opportunity PAR-21-068 from the NIH Guide for Grants and Contracts. This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-20-018.

Prohibition on Expending NIH Grant Funds for Covered Telecommunications Equipment or Services

November 23, 2020

Notice NOT-OD-21-030 from the NIH Guide for Grants and Contracts

Small Vessel VCID Biomarker Validation Consortium Sites (U01)(Clinical Trials Not Allowed)

November 23, 2020

Funding Opportunity RFA-NS-21-005 from the NIH Guide for Grants and Contracts. T?o invite applications to an open competition to be one of up to 7 supported sites in the next phase of the NINDS small vessel vascular contributions to cognitive impairment and dementia (VCID) biomarkers consortium. The original consortium, established under RFA-NS-16-019 and RFA-NS-16-020, pursued initial stages of multi-site validation of 11 candidate imaging-based and fluid-based biomarkers. The primary objective of the next 5 years is to carry out comprehensive multi-site clinical validation of up to six of these 11 biomarkers to be selected by the NINDS in a process separate from this FOA. The focus will be validation in longitudinal studies of diverse all-comers populations that are typical in clinical settings in the United States. The network of sites will provide scientific expertise and experimental infrastructure to pursue these goals synergistically including with the Coordinating Center (RFA-NS-21-004). At the conclusion of clinical validation each biomarker will have a designated category and context of use as defined by the FDA and a finalized public protocol that describes all details needed to utilize the biomarker. The sites will drive the consortium scientifically and contribute administratively to comprehensive rigorous clinical validation of biomarkers for future clinical trials, including in large phase III trials, and for generating scientific breakthroughs in our understanding and treatment of VCID.

Small Vessel VCID Biomarkers Validation Consortium Coordinating Center (U24 Clinical Trial Not Allowed)

November 23, 2020

Funding Opportunity RFA-NS-21-004 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to have an open competition to support a Coordinating Center for the next phase of the NINDS small vessel vascular contributions to cognitive impairment and dementia (VCID) biomarkers consortium. The original consortium was established under RFA-NS-16-019 and RFA-NS-16-020. The goal of the next phase, under RFA-NS-20-004 (Coordinating Center) and RFA-NS-20-005 (sites), is to complete clinical validation of biomarkers initially developed during the first 5-year funding cycle of this program. The Coordinating Center will consist of: (i) an Administrative Core responsible for organizing, coordinating and administratively driving Consortium activities; and (ii) a Data Core that will coordinate, receive, collect, and share data, including de-identified clinical data. The Coordinating Center will drive the consortium administratively and contribute scientifically to validation of biomarkers with specified context of use for future clinical trials, including in large phase III trials, with general and diverse populations, and for generating scientific breakthroughs in our understanding and treatment of VCID.

Graduate Research Training Initiative for Student Enhancement (G-RISE) (T32 - Clinical Trial Not Allowed)

November 20, 2020

Funding Opportunity PAR-21-026 from the NIH Guide for Grants and Contracts. The goal of the Graduate Research Initiative for Student Enhancement (G-RISE) program is to develop a diverse pool of scientists earning a Ph.D., who have the skills to successfully transition into careers in the biomedical research workforce. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-based approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This program is limited to applications from training programs at research-active institutions (i.e., those with a 3-year average of NIH Research Project Grant funding less than $7.5 million total costs).

Pre-Application Webinar for RFA-CA-20-054, Collaborative Approaches to Engineer Biology for Cancer Applications (U01 Clinical Trial Not Allowed)

November 19, 2020

Notice NOT-CA-21-017 from the NIH Guide for Grants and Contracts